Simon 2005.
Methods | Double‐blind, flexible‐dose, placebo‐controlled study |
Participants | 60 study participants meeting criteria for the A1, A2 and at least 1 additional ASD criterion (i.e., B, C and or D criteria), as determined by the Acute Stress Disorder Interview upon initial evaluation |
Interventions | Escitalopram (10 to 40 mg/day) versus placebo x 12 weeks |
Outcomes | Primary outcome: symptoms of post‐traumatic stress disorder, symptoms of acute stress disorder Secondary outcome: Clinical Global Improvement |
Notes | — |
ASD: acute stress disorder PTSD: post‐traumatic stress disorder